Skip to main content
. 2019 May 31;12(3):313–321. doi: 10.1093/ckj/sfz070

FIGURE 3.

FIGURE 3

Cardiovascular safety of SGLT2i and atrasentan. Data from (A) cardiovascular outcome trials enrolling T2DM patients at high cardiovascular risk (CANVAS Program, DECLARE-TIMI and EMPA-REG OUTCOME) [20, 33, 40] and (B) trials enrolling patients with DKD (CANVAS and SONAR) [2, 20] are presented. MACE: major cardiovascular events: cardiovascular death, myocardial infarction or stroke.